University of Khartoum
Faculty of Pharmacy

Assessment of Treatment of Neonatal Sepsis at Dr. Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan.

By:
Mohammed Ahmed Abdulrahman Alabbas

B. Pharm. (U of K) 2003

A thesis submitted in partial fulfillment of the (M CP) degree

Supervisors

Professor: Elamin Ibrahim Elnima.
Department of pharmaceutics
Faculty of Pharmacy
University of Khartoum

Dr: Amani A. Norry.
Head of pharmacy department - Dr. Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan

Khartoum
Sudan
October 2010
## Content:

<table>
<thead>
<tr>
<th>Subject</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Content</td>
<td>I</td>
</tr>
<tr>
<td>Dedication</td>
<td>III</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>IV</td>
</tr>
<tr>
<td>Abstract</td>
<td>V</td>
</tr>
<tr>
<td>Arabic abstract</td>
<td>VII</td>
</tr>
<tr>
<td>List of abbreviations</td>
<td>VIII</td>
</tr>
<tr>
<td>List of tables</td>
<td>X</td>
</tr>
</tbody>
</table>

### Chapter 1: Introduction and Literature

1.1-Introduction
   - 1.1.1-Defintion
   - 1.1.2-Classification and Etiology
   - 1.1.3-Risk factors
   - 1.1.4-Signs
   - 1.1.5-Investigations
   - 1.1.6-Treatment
     - 1.1.6.1-Supportive treatment
     - 1.1.6.2-Antimicrobial treatment
   - 1.1.7-Rationale
   - 1.1.8-Objectives

### Chapter 2: Methodology

2.1-Study design
2.2-Study area
2.3-Study population
2.4-Sample size
2.5-Criteria of selection
2.6-Method
2.7-Data analysis

Chapter 3: Result and Discussion

3.1-Results
3.2-Discussion

Chapter 4: Conclusion and Recommendations

4.1-Conclusion
4.2-Recommendations

References
Dedication

To the soul of my great father......

To my lovely mother and sisters......

To all who stand by me in my live......
Acknowledgment:

I would like to express my deepest thanks and grateful acknowledgment to my supervisor Professor: Elamin Ibrahim Elnima-Faculty of Pharmacy-University of Khartoum for his supervision and kind assistance and guidance and wise advices which made this research comes to light.

My thanks are extended to my co-supervisor Dr. Amani Norry-Head of pharmacy department - Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan for her continuous encouragement and valuable advices.

I would like also to thank all the staff of Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan and specially the statistics staff at Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan, and all others who supported me for conducting this research.
Abstract:

Introduction: Neonatal sepsis is considered as the most common cause of death at Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan. Mortality rate due to neonatal sepsis at the hospital was 24% of the total death in the hospital.

Objectives: The objective of this study was to assess the treatment of neonatal sepsis, to develop strategy for rational use of antibiotics to reduce the risk of antibiotics resistance, to evaluate the record keeping system and to evaluate the follow of the protocol of treatment of neonatal sepsis in the hospital.

Methodology: The study was a retrospective study conducted at Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan in the period of 9/ 2010 – 10/ 2010, tow hundred and twenty nine patients medication records out of 562 records were checked for type of antimicrobial treatment used and if supportive treatment was used, investigations done, duration of treatments, if the protocol was followed and the outcomes of these treatments. The data was analyzed using SPSS.

Results: Mortality rate was found to be 21.35% from total number of patient admitted and diagnosed as neonatal septicemia, CBC done for all patients (100%), Blood culture and Urine culture were not done for any studied cases (0%), all cases received supportive treatment (100%), 65.93% received Cefotaxime + Ampicillin + Cloxacillin combination was the most common used treatment, other combination were used with
variable frequencies, hospital protocol was followed in (21.9%) of the cases, 74.67% of patients were cured while 25.33% were dead.

Conclusion: The mortality rate due to neonatal sepsis was very high, supportive treatment is crucial and had been used for all patients, protocol follow-up was ignored for most of the cases and the selection of antimicrobial was irrational and not based on the type of the infection or the isolation of the causative organism, which will lead to emergence of resistance. The record keeping system was good enough to provide the required information.
ملخص الأطراف:

مقدمة: يعتبر الإقتصاد الوليد هو السبب الأكثر شيوعاً للوفاة في مستشفى د/جعفر بن عوف

الدكتور/ة: كان الهدف من هذه الدراسة تقييم معالجة الإقتصاد الوليد، ووضع استراتيجية

لترشيد استخدام المضادات الحيوية للحد من مخاطر مقاومة المضادات الحيوية، لتقييم نظام

حتل السجلات وتقييم تتابع بروتوكول علاج الأطفال حديثي الولادة المصابين بتعفن الدم في

المستشفى.

الطريقه: أجريت الدراسة في المستشفى بقرار رجعي في الفترة من عام 2010 / 9 - 10 / 2010

تمت مراجعة وبحث معتنات وسعور من مخالفات استناد وصوت

ملف وفحص السجلات لتنوع المضادات الحيوية المستخدمة، وإذا تم استخدام المعالجة

الداعمة، والفحصات التي أجريت لتشخيص المرض وتجربة العلاج المناسب، ومدة العلاج

وهل تم اتباع البروتوكول ونتائج هذه العلاجات. وتتم تحليل البيانات باستخدام التحليل

الإحصائي للعلوم الاجتماعية.

النتائج: وجد أن معدل الوفيات هو 21.35% من مجمل الوفيات بسبب الإقتصاد الوليد،

التحليل الكلي للدم اجري بنسبة 100%، لم يتم تزويج الدم والبول لمعرفة الإحياء.الدقيقة المسبب

للمرض وتحسسها للمضادات الحيوية المعين 0%، تلقي جميع المرضى علاج مساعدة

100%، تلقي 65.93% (سيفوتاكسين + أميسيلين + كلوكساسيلين الذي هو الأكثر

بين العلاج المستخدمة واستخدمت بعض المضادات الحيوية الأخرى بنسبة منفأته، تم اتباع

البروتوكول بمعدل (21.9 %)، وشفى 74.67% من المرضى بينما

الخاتمة: معدل الوفيات بسبب الإقتصاد الوليد عالي جداً، العلاجات الداعمة من الاتي مهم

وتم استخدامها لجميع المرضى، لم يتبع البروتوكول المتخصص لعلاج المرض كلياً واستخدام

المضادات المضادات الحيوية كان غير رشيد ولم يتم الاختيار على أساس نوع الكائن المسبب

للمرض أو نوع المرض(تصنيف)، مما سيؤدي إلى ظهور أجيال مقاومة للمضادات المتوفره

حالياً وكان نظام حفل السجلات جيداً بما فيه الكفاية لتوفير المعلومات المطلوبة.
List of abbreviations:

(GBS) = Group B Streptococcus.

(E. coli) = Escherichia coli.

(GI tracts) = Gastrointestinal tracts.

(GU tracts) = Genitourinary tracts.

(CRP) = C-reactive protein.

(WBC) = White Blood Cell.

(LBW) = Low Birth Weight.

(PROM) = Preterm Rupture of Membrane.

(CSF) = Cerebro Spinal Fluid.

(SIRS) = systemic inflammatory response syndrome.

(S. aureus) = Staphylococcus aureus.

(MRSA) = methicillin-resistant S. aureus

(NICU) = Neonatal intensive care unit.
(CoNS) = Coagulase-Negative Staphylococci

(CBC) = Complete Blood Count.

(BC) = Blood Culture.

(UC) = Urine Culture.

(S test) = Sensitivity test.

(CAC) = Cefotaxime+Ampicillin+Cloxacillin.

(CACV) = Cefotaxime+Ampicillin+Cloxacillin+Vancomycin.

(BG) = Benzyl Penicillin+Gentamycin.

(EONSFL) = Early Onset Neonatal Sepsis First line.

(LONSFL) = Late Onset Neonatal Sepsis First line.

(LONSSL) = Late Onset Neonatal Sepsis Second line.

(LONSTL) = Late Onset Neonatal Sepsis Third line.
List of tables:

1- Table 1 Gender.

2- Table 2 Age.

3- Table 3 Complete Blood Count.

4- Table 4 Blood Culture.

5- Table 5 Urine Culture.

6- Table 6 Sensitivity test.

7- Table 7 Supportive treatments.

8- Table 8 Antimicrobials used.

9- Table 9 Duration of treatment

10- Table Outcomes.

11- Table 11 Follow up of treatment protocol.
Chapter 1: Introduction and Literature Review

1.1-Introduction:
1.1.1-Definition:
Neonatal sepsis is a clinical syndrome that resembles invasive infection, usually due to bacterial infections in the neonatal period with multiple signs and symptoms, sepsis is commonest cause of neonatal morbidity and mortality, it is estimated that 20% of all neonate develop neonatal sepsis$^1$, which is responsible for 40-50% of neonatal death in developing countries$^2$.

1.1.2-Classification and Etiology:
Neonatal Sepsis can be classified into tow main groups according to the onset of symptoms$^3$:
Early onset which is present within the early 2 days (48hours) of life and late onset usually present after 2 days (48hours) or more from birth date. Early onset is occurring during passage of the fetus through the birth canal. The principal organisms that cause early-onset infection include predominantly group B streptococcus (GBS), Escherichia coli (E. coli)$^4$. The major risk factor for this type of neonatal sepsis is the asymptomatic colonization of the maternal gastrointestinal or genitourinary tracts$^5$. The maternal GI or GU tracts are colonized by GBS in up to 30% of pregnant women. Risk factors for higher colonization rates include African American descent and diabetes$^6$. Additional risk factors for early-onset infection include prolonged rupture of membranes, prematurity, male gender, low birth weight, maternal infection, and poor prenatal care$^7$. 

Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
Late-onset infection occur after delivery, due to the organism that may be acquired from environment such as hospital or at home, infections from common hospital pathogens, including bacteria (coagulase negative staphylococcal species), viruses, and fungi (Candida species). Neonates on antibiotics for any length of time are at higher risk for the developing late-onset infection, and also infants with central intravenous catheter, such as percutaneously-inserted central catheter, an umbilical arterial line, or an umbilical venous line. Neonates that are on ventilators for other reasons than sepsis may acquire an infection in the hospital (nosocomial infections)\textsuperscript{8}

Late-onset neonatal sepsis may occur in infants after leaving the hospital, so the causative organisms is similar as in early-onset sepsis, GBS, E. coli and other Gram-negative species\textsuperscript{9}.

1.1.3-Risk Factors:

- Ruptured membrane for prolonged period of time (more than 24 hours).
- Prematurity associated with premature rupture of membrane.
- Preterm labour with no adequate explanation
- Fetal distress without adequate explanation (fetal heart rate abnormalities especially fetal tachycardia, passage of meconium).
- Evidences of infection or maternal infection.
- Amniotic fluid with foul smelling or malodorous baby
- Indwelling vascular catheter.
1.1.4-Signs of Sepsis in the Newborn

Signs are nonspecific and subtle and can not be used as only method for diagnosis of neonatal sepsis and to distinguish among causing organism, the common signs include:

- Hypothermia, Fever and/or instable temperature.
- Respiratory distress.
- Apnoea and bradycardia
- Cyanotic episodes and unexplained jaundice and hepatomegaly.
- Poor feeding, irritability, lethargy and seizures.
- Hypoglycemia, hyperglycemia and unstable blood sugar.
- Abdominal distension and bile-stained aspirates
- Skin rashes and umbilical flare.
- Poor peripheral perfusion.
- Pallor.

1.1.5-Investigations:

1.1.5.1-Full blood count:

Differential white cell count (Normal WBC 10-30,000 x 10^9/L) and percentage left shift (immature neutrophils/total neutrophil count). If >20% this is moderately predictive of sepsis, low WCC especially with neutropenia is also suspicious of sepsis.

1.1.5.2-Blood cultures:

For the isolation of the causative organism and for sensitivity tests.
1.1.5.3-Urine routine and culture:

For the isolation of the causative organism and for sensitivity tests.

1.1.5.4-Chest radiograph:

To confirm the diagnosis in some cases.

1.1.5.5-C-Reactive Protien

1.1.5.6-Gastric aspirate and skin/wound swabs:

Generally done at birth only.

1.1.5.7-Lumpur Puncture-Cerebrospinal fluid:

Needed for all cases of late onset and some cases in early onset sepsis

1.1.6-Treatment of Neonatal sepsis:

Treatment of neonatal sepsis can be categorized into tow main groups: Supportive treatments which include (providing thermo-neutral environment, respiratory support, volume expanders and blood transfusion if needed\textsuperscript{10}.

And antimicrobial treatment which is used based on onset of the infection and the causative organism according to the sensitivity test, and the duration of treatment depend on the type of the infection. Standard text books recommend 14-day antibiotic therapy for culture-proven neonatal sepsis\textsuperscript{11}. 
1.1.6.1-Supportive treatment:
The importance of supportive therapy split from the good understand of sepsis and the systemic inflammatory response syndrome (SIRS) with the subsequent effects of hypotension, diminished perfusion, thrombocytopenia and coagulation. Splanchnic hyperemia in premature infants, as seen in adults SIRS is due to sepsis\textsuperscript{10}.

For managing all sick infants effectively, electrolyte balance and fluid with proper observation of inputs and outputs records is crucial, with regular monitoring of serum electrolytes and blood glucose dyslectrolytemia can be avoided and euuglycemia can be maintained. Fluid intake can be assessed by using the volume and specific gravity of the urine.

Blood pressure should be undertaken regularly and so all other vital signs to avoid hypotension and accompanied shock.

Infant's condition may require some vasopressors Intropes (eg. Dopamine and Dobutamine) can be used\textsuperscript{12}.

Some cases may require the transfusion of frozen plasma and platelets. The use of these compounds must be monitored to avoid any subsequent complications such as fluid overload or any unpredictable outcomes.

Central catheter must be removed if there any suspicion of sepsis and can be reinserted 3-5 days after stabilization of therapy.

Good monitoring of fluid input and output will maintain good blood pressure and permit proper perfusion of renal and so the danger of renal failure will be diminished.

All infants especially very low birth weight and preterm require supportive ventilation to improve respiratory status.
Total parental nutrition is essential for most patients and it is better to be
tailored according to the patient needs\textsuperscript{13}.

1.1.6.2-Antimicrobial therapy:

Beside to the supportive therapy to restore the vital signs, antimicrobial is
also required for treatment of neonatal sepsis. The selection of
antimicrobial agent is depend on the type sepsis and causative organism.
As an example in the early onset sepsis its better to use a combination of
agents that treat group B streptococcus as well as Gram-negative species.
Useful agents include ampicillin and gentamicin, or ampicillin plus
cefotaxime. They used in combination to be a broad spectrum of the most
common pathogens in early-onset sepsis, they penetrate CNS excellently.
Ampicillin and gentamicin is the first line for treatment of early sepsis\textsuperscript{14}.
Gentamycin need close monitoring of renal function.

For late-onset sepsis, the selection of antimicrobial should be knowledge
of the causative organism after culture and sensitivity tests. Ampicillin
and Gentamycin can be used empirically as in early onset neonatal sepsis
if the causative agents are sensitive to them.
In the presence of central line treatment should cover S. aureus and
coagulase-negative staphylococci.
In case of methicillin-resistant S. aureus or MRSA in infants with line
infections, the first lines antimicrobial will be vancomycin, plus an
aminoglycoside such as gentamicin, for empiric coverage of Gram-
negative bacilli until the result of culture is received.
In case of non controlled bacteremia and the sepsis is still progressed with
adequate selection of broad spectrum antibiotics and presences of
fungemia the infected central line must be removed. Neonates admitted to neonatal intensive care unit (NICU) from community, antimicrobial used must cover meningitis treatment. Cephalosporin of third generation (i.e., cefotaxime or ceftriaxone) plus ampicillin should be included in the empiric therapy.

The clinical progress and microbial result must be reviewed at 48 hours, stop therapy if patient is well and culture is negative, continue if there are signs of sepsis and culture is positive and if anaerobic infections is suspected add metronidazole.

Some antibiotics were reserved for resistant organism and used after sensitivity test is performed (eg. Meropenem, Aztreonam and imipenem).

For G-ve use Aztreonam, Meropenem is active against most bacteria except methicillin resistant saph aureus (MRSA).

Imipenem reported to cause seizures and should be avoided in neonates.

<table>
<thead>
<tr>
<th>Early Onset Neonatal Sepsis</th>
<th>Late Onset Neonatal Sepsis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First line:</strong></td>
<td><strong>First line:</strong> Flucloxacillin and Amikacin</td>
</tr>
<tr>
<td>Ampicillin and Gentamycin</td>
<td>Staphylococcus aureus is sensitive to Flucloxacillin.</td>
</tr>
<tr>
<td></td>
<td>Coagulase negative staphylococcus is resistant to Gentamycin but sensitive to Amikacin.</td>
</tr>
<tr>
<td></td>
<td>To cover Enterococci, strep fecaelis, listeria and GBS Ampicillin must be added.</td>
</tr>
<tr>
<td></td>
<td><strong>Second line:</strong> Cefotaxime/Ceftazidime</td>
</tr>
<tr>
<td></td>
<td>In case of meningitis and resistant klebiella.</td>
</tr>
<tr>
<td></td>
<td><strong>Third line:</strong></td>
</tr>
<tr>
<td></td>
<td>If resistant staph or the patient is deteriorated or ill use Vancomycin and Amikacin.</td>
</tr>
<tr>
<td></td>
<td>If pseudomonas is suspected use Piperacillin and Amikacin.</td>
</tr>
</tbody>
</table>
Duration of treatment:

In general, empiric treatment of neonatal sepsis should be continued for 7-10 days, providing there is improvement in the overall condition of the patient. In many cases, the neonate will have all the clinical features of sepsis and will have improved after institution of antimicrobial therapy but will fail to yield a positive culture. In these instances it is appropriate to continue a full course (7-10 days) of antibiotics, despite the absence of a specific organism. Longer durations (up to 3 weeks) of antibiotic therapy may be used in cases of pneumonia or meningitis.

<table>
<thead>
<tr>
<th>Type of infection</th>
<th>Duration of treatment/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive septic screen and negative blood culture</td>
<td>7 – 10</td>
</tr>
<tr>
<td>Positive blood culture without meningitis</td>
<td>7 – 14</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>7 – 10</td>
</tr>
<tr>
<td>Meningitis</td>
<td>21</td>
</tr>
</tbody>
</table>
Summary Sheet of Antibiotic Guidelines for Early and Late Sepsis

- Clinical signs and symptoms highly suggestive of bacterial infection.
- Risk factors for sepsis such as prolonged ruptured membranes (see Guideline C6).
- Infants with clinical signs compatible with infection such as respiratory distress.
- Unexpectedly poor condition at birth.

1. Suspected Sepsis
   - <48hrs
     - Early Sepsis
       - Diagnostic Tests (see section 3)
         - Benzyl Penicillin and Gentamicin
           - +ve culture
             - Assess illness severity
               - well
                 - Stop treatment at 48 hrs
               - unwell
                 - 7 days treatment
                   - no response or worsens
                     - Discuss with Consultant, consider Cefotaxime & Gentamicin AFTER repeat cultures
                   - well
                     - Stop treatment at 48 hrs
               - -ve culture
                 - 7 days treatment
                   - no response or worsens
                     - Discuss with Consultant, consider Cefotaxime & Gentamicin OR Vancomycin & Gentamicin depending on clinical situation AFTER repeat cultures
           - -ve culture
             - Assess illness severity
               - well
                 - Stop treatment at 48 hrs
               - unwell
                 - 7 days treatment
                   - no response or worsens
                     - Discuss with Consultant, consider Cefotaxime & Gentamicin OR Vancomycin & Gentamicin depending on clinical situation AFTER repeat cultures
     - >48hrs
       - Late Sepsis
         - Diagnostic Tests (see section 3)
           - Flucloxacillin and Gentamicin
             - +ve culture
               - Assess illness severity
                 - well
                   - Stop treatment at 48 hrs
                 - unwell
                   - 7 days treatment
                     - no response or worsens
                       - Discuss with Consultant, consider Cefotaxime & Gentamicin OR Vancomycin & Gentamicin depending on clinical situation AFTER repeat cultures
             - -ve culture
               - Assess illness severity
                 - well
                   - Stop treatment at 48 hrs
                 - unwell
                   - 7 days treatment
                     - no response or worsens
                       - Discuss with Consultant, consider Cefotaxime & Gentamicin OR Vancomycin & Gentamicin depending on clinical situation AFTER repeat cultures

NB: If positive culture or clinical suspicion of specific site infection see guideline details (Pneumonia, Necrotising Enterocolitis, Meningitis, UTI, Endocarditis, Bone & Joint)
1.1.7-Rationale:

The number of patients admitted to Dr. Gaafar Ibnauf specialized children's hospital-Khartoum-Sudan and diagnosed as neonatal sepsis in the period of January 2010 up to October 2010 was 562, 120 patients were dead which represent 21.35% of the total number of the patients. Total number of patients dead in the this study period was about 500 death, the death due to neonatal sepsis in the hospital was 120 which represents 24% of the total death in the hospital. This high percent of mortality due to neonatal sepsis reflect the fact that the sepsis was not managed efficiently. The irrational use of antibiotics in the hospital will lead to emergency of resistance; moreover the cost of these medications is very high compared to the use of Benzyl Pecillin, Gentamycin and other effective – low cost agents which considered as a burden to the hospital budget.
Objectives:

General objective:

To assess the treatment of neonatal sepsis in Gaffar Ibnauf hospital.

Specific objective:

To develop strategy for rational use of antibiotics in the hospital.
To reduce the risk of antibiotics resistance.
To evaluate the record keeping system.
To evaluate the follow of the protocol of treatment of neonatal sepsis in the hospital.
1.2-Literature Review:

AuranqzwB. and Hameed A. conducted study about the Neonatal sepsis in hospital –born babies: bacterial isolates and antibiotic susceptibility patterns, the objective of the study is to determine the frequency of bacterial isolates from neonatal blood cultures and their susceptibility patterns in hospital-born babies having sepsis. It was an observational study carried out at Obstetrics Unit and Special Care Baby Unit of Khyber Teaching Hospital, Peshawar from 1st January to 31st December 2001. This study was carried out on the neonates born and admitted in hospital with positive blood culture reports. Early onset neonatal sepsis and late onset neonatal sepsis were defined as illness appearing from birth to seven days and from eight to twenty-eight days postnatal age respectively. The blood culture reports were analyzed by SPSS package and cross tabulation was done. The result of the study was found to be: One hundred and twelve hospital-born babies presented with sepsis. Sixty-seven neonates had positive cultures. Escherichia coli (E. coli) was the commonest organism causing EONNS (35; 77.1%) followed by Pseudomonas (4; 8.9%), Klebsiella (4; 8.9%) and Staphylococcus aureus (2; 4.4%) respectively. In the late onset neonatal sepsis E. coli (19; 77.3%) was the commonest followed by Staphylococcus and Pseudomonas (2; 9% each) and Klebsiella (1; 4.5%). The gram-negative organisms showed high degree of resistance to commonly used antibiotics, ampicillin (79.3%), amoxicillin (74.6%) and ceftazidime (71.6%), cefotaxime (55.2%) and comparatively low resistance to gentamicin (43.2%), tobramycin (34.3%), imipinem (23.6%), amikacin (22.3%), ofloxacin and ciprofloxacin (11.9%) respectively. Staphylococcus aureus showed almost the same resistance to ampicillin,
75\%, and comparatively low resistance to the rest of the antibiotics as compared to the gram-negative organisms. 
The conclusion is that Neonatal sepsis is mainly caused by gram-negative organisms, which are developing resistance to commonly used antibiotics\textsuperscript{21}.

B Muller-Pebody and his colleagues conduct a study about the Empirical treatment of neonatal sepsis: are the current guidelines adequate? The Objectives of the study was to use national laboratory surveillance data to determine whether pathogens responsible for neonatal bacteraemia were sensitive to nationally recommended antibiotic regimens. Design All reports of neonatal bacteraemia received by the Health Protection Agency's voluntary surveillance scheme in England and Wales from January 2006 until March 2008, were extracted from the database. Organisms were ranked by frequency, and proportions susceptible to antimicrobials recommended for empirical treatment of neonatal sepsis were determined. Results There were 1516 reports of bacteraemia for neonates <48 h old (early-onset) and 3482 reports for neonates 2-28 days old (late-onset). For early-onset bacteraemia, group B streptococcus (GBS) was the most frequent pathogen (31\%) followed by coagulase-negative staphylococci (CoNS; 22\%), non-pyogenic streptococci (9\%) and Escherichia coli (9\%). For late-onset bacteraemia, CoNS were isolated most frequently (45\%), followed by Staphylococcus aureus (13\%), Enterobacteriaceae (9\%), E coli (7\%) and GBS (7\%). More than 94\% of organisms (early-onset) were susceptible to regimens involving combinations of penicillin with either gentamicin or amoxicillin, amoxicillin combined with cefotaxime or cefotaxime monotherapy. More than 95\% of organisms (late-onset) were susceptible to gentamicin with either flucloxacillin or amoxicillin and amoxicillin with cefotaxime, but
only 79% were susceptible to cefotaxime monotherapy. Conclusions Current guidelines for empirical therapy in neonates with sepsis are appropriate. However, gentamicin-based regimens should be used in preference to cefotaxime-based treatments, because of lower levels of susceptibility to cefotaxime and the need to avoid exerting selective pressure for resistance. Surveillance data linked to clinical data should further inform rational antibiotic prescribing in neonatal units. T. B. Yves liem and his colleagues conducted a study which received 24 November 2009; returned 17 January 2010; revised 8 March 2010; accepted 8 March 2010 it was about variation in antibiotic use in neonatal intensive care units in Netherland, the Objectives of the study is to examine the variation in quantity and classes of antibiotics used in all 10 tertiary care neonatal intensive care units (NICUs) in the Netherlands during 2005. They collect data from all tertiary care NICUs in the Netherlands on clinical and demographic characteristics and the type and quantity of systemic antibiotic use [expressed as defined daily doses (DDD)/100 admissions] in 2005. Antibiotics were ranked by volume of DDDs, and those antibiotics which accounted for 90% of the total volume of use [drug utilization (DU) 90%] were noted. They found that Antibiotic consumption ranged from 130 to 360 DDD/100 admissions. In total, 9–24 different antibiotics were used, of which 3–10 were in the DU90% segment. They conclude that by comparing antibiotic use in Dutch NICUs they found a considerable variation in the number of different antibiotics used and in the total amount of antibiotic use. Further exploration of the opportunities to reach consensus in antibiotic policy, and to increase attention to antibiotic stewardship, is recommended.
Chapter 2:

Methodology:-

2.1- Study design:-
A retrospective cross-sectional study design was carried out in this research, the relevant data was collected from patient's files which contain the patients medication records using data collecting sheet which include the followings:-

- Patient file number.
- Patient sex.
- Patient age.
- Antimicrobial treatment selected (Benzyl Penicillin, Gentamycin, Amikacin, Cefotaxime, Ceftrixone, Metronidazole, Vancomycin, (ampicillin+Cloxicillin), Meropenem, Antifungal and Antiviral).
- Duration of treatments.
- Supportive treatment was used or not. (Yes or No).
- Protocol was followed or not. (Yes or No).
- Patient cured or not.

2.2- Study area:-
The study was carried at Dr.Gaafar Ibnauf specialized children's hospital- Khartoum-Sudan.
2.3-Study population:-
Patients admitted to Dr.Gaafar Ibnauf specialized children's hospital and diagnosed and treated for neonatal sepsis in the period from January 2010 up to October 2010.

2.4-Sample size:-

The sample size of this study was calculated using the following equation:-

\[
 n = \frac{N \cdot z^2 \cdot P \cdot q}{(n-1)d^2 + z^2 \cdot P \cdot q}
\]

\[
 n = \frac{562 \cdot (1.96)^2 \cdot 0.5 \cdot 0.5}{561 \cdot (0.05)^2 + (1.96)^2 \cdot 0.5 \cdot 0.5} = 229
\]

Where:
N = Population under Study.
n = Sample size.
Z = Value of normal curve corresponding to level of confidence (95% =1.96).
P = Proportion of target group.
q = 1-p.
d = desired margin of error 5%.

From the above mentioned equation the sample size of this study was equal to 229.

2.5-Criteria of selection:-

All patients diagnosed and treated for neonatal in the period from January 2010 up to October 2010 in all units at Dr.Gaafar Ibnauf specialized children's hospital-Khartoum-Sudan.
2.6-Method:-

Patients medication records were checked for the following:-
- Patient file number.
- Patient sex.
- Patient age.
  - Antimicrobial treatment selected (Benzyl Penicillin, Gentamycin, Amikacin, Cefotaxime, Ceftrixone, Metronidazole, Vancomycin, (ampicillin+Cloxicillin), Meropenem, Antifungal and Antiviral).
  - Duration of treatments.
  - Supportive treatment was used or not. (Yes or No).
  - Protocol was followed or not. (Yes or No).
  - Patient cured or not.

2.7-Data analysis:-

The data was analyzed using Microsoft Excel Sheet and SPSS.
Chapter 3:  
Result and Discussion:-

3.1-Results:-

During the period of the study 229 files and patients medications records were revised and checked for the followings:
Gender, Age, Investigations, Supportive treatment, Antimicrobial treatment, Duration of treatment, Protocol follow-up and Outcomes.
The following results were obtained after analysis of data.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>123</td>
<td>53.71</td>
</tr>
<tr>
<td>Female</td>
<td>106</td>
<td>46.29</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (1) Gender

<table>
<thead>
<tr>
<th>Age</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-48 hours</td>
<td>20</td>
<td>8.73</td>
</tr>
<tr>
<td>More than 48 hours</td>
<td>209</td>
<td>91.27</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (2) Age  
Early neonatal sepsis if age was 0 - 48 hours.  
Late neonatal sepsis if age was more than 48 hours.

<table>
<thead>
<tr>
<th>CBC</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Done</td>
<td>229</td>
<td>100</td>
</tr>
<tr>
<td>Not done</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (3) CBC.
<table>
<thead>
<tr>
<th>Blood culture</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Done</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Not done</td>
<td>229</td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (4) Blood Culture.

<table>
<thead>
<tr>
<th>Urine culture</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Done</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Not done</td>
<td>229</td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (5) Urine Culture.

<table>
<thead>
<tr>
<th>Sensitivity test</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Done</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Not done</td>
<td>229</td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (6) Sensitivity Test.

<table>
<thead>
<tr>
<th>Supportive treatment</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provided</td>
<td>229</td>
<td>100</td>
</tr>
<tr>
<td>Not provided</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (7) Supportive treatment.
<table>
<thead>
<tr>
<th>Medications used</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezyl penicillin inj+Gentamycin inj</td>
<td>15</td>
<td>6.60</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin)</td>
<td>151</td>
<td>65.93</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin) + Vancomycin inj</td>
<td>30</td>
<td>13.10</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin) + Acyclovir inj+Fluconazole inj</td>
<td>1</td>
<td>0.20</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin) + Meropenem inj</td>
<td>8</td>
<td>3.50</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin) + Metronidazole inj</td>
<td>17</td>
<td>7.50</td>
</tr>
<tr>
<td>Cefotaxime inj+Ap miclox inj (Cloxacillin+Ampicillin) + Amikacin</td>
<td>5</td>
<td>2.20</td>
</tr>
<tr>
<td>Ceftriaxone inj+ Ap miclox inj (Cloxacillin+Ampicillin)</td>
<td>2</td>
<td>0.90</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (8) Antimicrobials used.

<table>
<thead>
<tr>
<th>Duration of treatment</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-2 Days</td>
<td>40</td>
<td>17.46</td>
</tr>
<tr>
<td>3-7 Days</td>
<td>150</td>
<td>65.50</td>
</tr>
<tr>
<td>More than 7 days</td>
<td>39</td>
<td>17.04</td>
</tr>
</tbody>
</table>

Table No. (9) Duration of treatment

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cured</td>
<td>171</td>
<td>74.67</td>
</tr>
<tr>
<td>Death</td>
<td>58</td>
<td>25.33</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (10) Outcomes.
<table>
<thead>
<tr>
<th>Follow up of protocol</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>followed</td>
<td>50</td>
<td>21.9</td>
</tr>
<tr>
<td>Not followed</td>
<td>179</td>
<td>78.1</td>
</tr>
<tr>
<td>Total</td>
<td>229</td>
<td>100</td>
</tr>
</tbody>
</table>

Table No. (11) Follow up of treatment protocol.
3.2-Discussion:

During the study period and after calculation of the sample, 229 files and medication records of patients diagnosed and treated for neonatal sepsis were checked for Gender, Age, Investigations, Supportive treatment, Antimicrobial treatment, Duration of treatment, Protocol follow-up and Outcomes.

An epidemiological survey of neonatal sepsis in a hospital in western Nigeria carried out by DO Awoniyi and his colleagues they found that the prevalence of bacterial infection was higher in samples obtained from male (65%) neonates than from females (35%). The majority of the patients studied were aged between 1-9 days but the result did not differ significantly from other age group.

We found that the prevalence of neonatal sepsis in male was 53.71% (Table (1)) which is higher than in female 46.29% (Table 1), and that confirm the fact that male gender is considered as a risk factor for neonatal sepsis.

A study titled (Neonatal infections in England: the NeonIN surveillance network) Conducted by Vergnano S. and his colleagues Designed as prospective multicentre surveillance using a web-based database linked to 12 English neonatal units. They measure: Incidence, age at infection, pathogens and antibiotic resistance profiles. They found that the incidence of early onset sepsis (EOS; =48 h of age) was 0.9/1000 live births and the incidence of late onset sepsis (LOS; >48 h of age) was 3/1000.
In our study, the incidence of early neonatal sepsis to late neonatal sepsis were 8.73% and 91.27% respectively (Table 2), this high incidence of late neonatal sepsis indicate that the neonates acquired the causative microorganism from the surrounding environment either from hospital or home and that may be due to improper handling of the neonate or the low hygiene at home.

Complete Blood Count (CBC) is one of the diagnostic methods of infectious diseases.
In our study the CBC was performed for all cases 100% (Table 3).

The diagnosis of neonatal sepsis, the isolation of causative organism, and the proper selection of the most effective and efficient antimicrobial depend mainly on blood culture and urine culture.

In study conducted From February 2003 to December 2004, at Neonatal Unit of Ghurki Trust Teaching Hospital, attached with Lahore Medical & Dental College Lahore by Rizwan Waseem and his colleagues,
The objectives were to find out the bacterial pathogens in neonatal sepsis and to determine antimicrobial sensitivity patterns of these pathogens.
They found that Escherichia coli was the commonest organism isolated, followed by Klebsiella, Pseudomonas, Staph. aureus, Staph epidermidis, Enterobacter, Acinobacter, Serratia and Streptococcus.
E. Coli constituted 33.37% of the early onset group, and 33.33% of late onset group.
Klebsiella constituted 34.37% and 22.22% while Pseudomonas 12.5% and 13.88% of early and late onset groups respectively. Enterobacter spp. was present only in the late, while Streptococcus in the early onset sepsis. Acinobacter, Staph. aureus and Staph. Epidermidis affected both the early and late onset groups.
In our study 0% of the studied cases had been blood cultured (Table 4), and 0% urine cultured (Table 5), no isolation of the causative organisms and the selection of the antimicrobial treatment was done empirically, this let to irrational use of antibiotics which will lead to emergency of resistance to these agents used.

The selection of the best antimicrobial treatment based on the sensitivity of the isolated organism to the specific antimicrobial agent.

The study above mentioned\textsuperscript{26} was also aimed to determine the sensitivity of the isolated pathogens to different antimicrobial agents. They found that all of the isolated were having a low sensitivity to Ampicillin, Gentamicin and Cefotaxime, while most of the organisms were sensitive to Ceftazidime, Amikacin and Imipenem. E. coli showed sensitivity of 14.70% to Ampicillin, 17.6% to Gentamicin, 41.17% to Cefotaxime, 61.76% to Amikacin, 79.4% to Ceftazidime and 97.05% to Imipenem.

Klebsiella and Pseudomonas also showed a low sensitivity to Ampicillin, Gentamicin, and Cefotaxime, while good sensitivity to Amikacin, Ceftazidime and Imipenem\textsuperscript{26}.

In our study no blood culture 0%(Table 4), and/or urine culture 0% Table (5) were performed, so neither isolation of causative microorganisms nor sensitivity test 0%(Table 6) were done. Antimicrobial agents were chosen regarding less to causative organisms and this also shows an irrational use of antibiotics in the hospital and of course the emergence of resistance to the used agents.

We found that supportive treatments (Intravenous fluids, Human albumin, Parental Nutrition, Thermal and Incubation) were received by
all of the sample patients 100% (Table 7) as recommended in management of neonatal sepsis for maintenance of neonate vital signs.

A study about the Empirical treatment of neonatal sepsis: are the current guidelines adequate? Was conducted by Muller-Pebody B and his colleagues the objectives of the study were to use national laboratory surveillance data to determine whether pathogens responsible for neonatal bacteraemia were sensitive to nationally recommended antibiotic regimens.

All reports of neonatal bacteraemia received by the Health Protection Agency's voluntary surveillance scheme in England and Wales from January 2006 until March 2008, were extracted from the database. Organisms were ranked by frequency, and proportions susceptible to antimicrobials recommended for empirical treatment of neonatal sepsis were determined.

They found that More than 94% of organisms (early-onset) were susceptible to regimens involving combinations of Penicillin with either Gentamicin, Amoxicillin combined with Cefotaxime or Cefotaxime monotherapy. More than 95% of organisms (late-onset) were susceptible to Gentamicin with either Flucloxacillin or Amoxicillin and Amoxicillin with Cefotaxime, but only 79% were susceptible to Cefotaxime monotherapy.

And concluded that Current guidelines for empirical therapy in neonates with sepsis are appropriate. However, Gentamicin-based regimens should be used in preference to Cefotaxime-based treatments, because of lower levels of susceptibility to Cefotaxime and the need to avoid exerting selective pressure for resistance.
In our study the antimicrobials agent used were as following:

The most of the patients 65.93% were received the combination of Cefotaxime and Ampicillin plus Cloxacillin (Ampiclox) (Table 8), and it was prescribed regardless to blood culture, urine culture and sensitivity tests, this regimen which contain Ampicillin and Cloxacillin was used for the concern about Ampicillin which was recommended by the most of protocols in combination with either Gentamycin injection, Amikacin injection or third generation cephalosporin (eg. Cefotaxime), but the presence of Cloxacillin make it one of the drawbacks of this regimen because it will lead to development of resistant organisms, the Gentamycin-based regimen (in combination with Benzyl Penicillin inj) was prescribed for only 6.6% of the patients (Table 8), and as mentioned in the above study conclusion, the Gentamicin-based regimens should be used in preference to Cefotaxime-based treatments, because of lower levels of susceptibility to Cefotaxime and to avoid development of resistant microorganisms.

The second most used combination was Cefotaxime inj + Ampiclox inj (Cloxacillin + Ampicillin) + Vancomycin inj represents 13.10% (Table 8) which also prescribed regardless to blood culture, urine culture and sensitivity tests, the addition of Vancomycin injection to this regiment due to susceptibility of MRSA infection, Vancomycin was added after the delay in recovery of patients. The use of this combination must be restricted for resistant cases and after isolation of causative organism and sensitivity test which was totally ignored in all of these cases, and the consequences of this irrational use of antibiotics are the generation of resistant microorganism and the high economical burden on hospital budget.
The third most used combination was Cefotaxime inj+Ap miclox inj(Cloxacillin+Ampicillin) +Metronidazole inj 7.5% (Table8), The Metronidazole was added to cover aerobic and anaerobic microorganism but also regardless the causative agent.

Combination of Gentamycin injection and Benzyl Penicillin injection prescribed for only 6.6% of patients (Table8), this regimen which Gentamycin-based was recommended by lot of authorities\textsuperscript{28}, but it was rarely used and this maybe due to the fair of treating doctors from resistant organisms and the severe illness of the neonates admitted to the hospital.

Cefotaxime inj+Ap miclox inj(Cloxacillin+Ampicillin)+Meropenem inj combination prescribed foe 3.5% of the patients(Table 8), this combination was also used regardless the isolation of the causative organisms and Meropenem inj was added due to the delay in response to the Cefotaxime inj+Ap miclox inj(Cloxacillin+Ampicillin) combination and the severe illness of the neonate, in spite of the fact that it’s reserved drug and not recommended for use in pediatric patients, and can be used for patients hospitalized for long periods and patients with complicated conditions who tried other antibiotics without improvement.

Cefotaxime inj+Ap miclox inj(Cloxacillin+Ampicillin) +Amikacin combination used for 2.2% of the patients (Table 8), to cover most of organism, it was used regardless the isolation of causative organism and this also may lead to emergence of resistance.

Ceftriaxone inj+ Ap miclox inj(Cloxacillin+Ampicillin) combination used for 0.9% of the patients (Table 8), it wasn’t recommended as first line but
due to lack of knowledge of causative organism it was used as empiric therapy and this also may lead to emergence of resistance.

Cefotaxime inj+Ap miclox inj (Cloxacillin + Ampicilllin) + Acyclovir inj + Fluconazole inj combination used for 0.2% of the patients (Table 8) to cover all suspected infections bacterial, fungal and viral (Neonatal sepsis can be of bacterial and/or fungal and/or viral infections) this is considered as empiric therapy to cover all possible infections.

There are different protocols regarding the use of antimicrobial in managing neonatal sepsis, here we will stack to the protocol approved and used in the hospital which is the study area.

There are different lines for treatment of neonatal sepsis based on the type of infection and the causative organism as stated in the introduction, the follow-up of these lines were studied, and the results were:

Early onset neonatal sepsis first line (Ampicillin or Benzyl Penicillin injection and Gentamycin) used for 6.6% of the patients.
Late onset neonatal sepsis first line (Flucloxacillin and Amikacin) was not used for any case 0% (table 8).
Late onset neonatal sepsis second line (to the first line adds Cefotaxime/Ceftazidime) was not used for any case 0% (table 8).
Late onset neonatal sepsis third line (Vancomycin 13.10% and Amikacin 2.2%) (Table 8).
The hospital protocol was followed in 21.9% of the studied cases.
The duration of treatment as mentioned in the introduction vary from 48 hours up-to more than three weeks.

Gathwala G, and his colleagues conducted a study titled: Ten days vs. 14 days antibiotic therapy in culture-proven neonatal sepsis. The objective of the study was to compare the effectiveness of a 10-day course of antibiotic therapy with the conventional 14-day course in blood culture-proven neonatal sepsis. They concluded that Ten-day antibiotic therapy is as effective as 14-day therapy in blood culture-proven neonatal sepsis, if the infant has achieved clinical remission by Day 7 of therapy 28.

In our study the duration of treatment for the studied cases were: 17.46% of patients were treated for 0 – 48 hours, 65.50% of patients were treated for 3 – 7 days which represent the most common duration of treatment and 17.04% of studied cases treated for more than 7 days due to very severe sepsis (Table 9).

Outcomes of the treatment for the studied cases were found to be as following:
The improved and cured and discharged neonates were 74.67% of the studied cases Table (10).
The percent of the patient not cured was 25.33% Table (10) which is high percent that indicates the need for establishing strategies to reduce this high mortality rate.
Chapter 4:

Conclusion and Recommendations:

4.1-Conclusion:

Mortality rate due to neonatal sepsis at Dr.Gaffar Ibnauf specialized children's hospital – Khartoum – Sudan was 24% of the total death in the hospital, 562 patients were diagnosed and treated as neonatal sepsis, 120 patients out of the 562 patients were dead which represents 21.35% of the neonatal sepsis patients, the diagnosis was done depending mainly on clinical signs and CBC, all patients received supportive treatment, the selection of antimicrobial was empirically not based on blood or urine culture or sensitivity tests, the most used combination was Cefotaxime+Ampicillin+Cloxacillin which represent 65.93% (Table 8) for all types of neonatal sepsis regardless the causative organism, some cases treated using other combination when the above mentioned treatment failed to treat the case effectively and efficiently, which include Cefotaxime+Ampicillin+Cloxacillin+Vancomycin combination used in 13.1% (Table 8), in which vancomycin was added after the suspicion of MRSA without cultures, Cefotaxime inj+Apmiclox inj(Cloxacillin+Ampicillin) +Metronidazole inj combination used for 7.5% (Table8) to cover anaerobic infections, Cefotaxime inj+Ampiclox inj(Cloxacillin+Ampicillin) +Acyclovir inj+Fluconazole inj used in 0.2% (Table 8) for very ill neonate to cover as possible infections. Cefotaxime inj+Ampiclox inj(Cloxacillin+Ampicillin)+Meropenem inj combination
prescribed for 3.5% (Table 8). Cefotaxime inj+Ap miclo x inj ( Cloxacillin+ A mpicillin) + Amikacin combination used for 2.2% of the sample cases (Table 8). Ceftriaxone inj+ A pmiclox inj ( Cloxacillin+Ampicillin) combination used for only 0.9% of the patients (Table 8). Finally Benzyl penicillin inj+Gent amycin inj combination which used for 6.6% of the patients (Table 8).

The protocol of the treatment of neonatal sepsis was followed only in 21.9% of the studied cases and that indicate to an irrational use of antibiotics in most of the studied cases,

The outcomes of the treatment was 74.67% of the patients were cured and 25.33% of the patients were not cured (died) either due to improper selection of antimicrobial or the severity of the illness in which the patients arrived the hospital in a complicated conditions and very severe sepsis.

The records keeping system in the hospital was proper, but more effort is needed to use computer database to make it easier to evaluate different treatment for different diseases and to easy the access to patient's medication records without violence of privacy and confidentiality of patients.
4.2-Recommendations:

New strategies should be established in order to reduce this high mortality rate and the irrational use of antibiotics.

The selection of antimicrobial for treatment of neonatal sepsis must be based on the type of the infection and the isolation of causative organism through blood culture, urine culture and sensitivity tests.

Pharmacist as health care provider and because they are familiar with medication must be more involved in prevention of irrational use of antibiotics, so antimicrobial stewardship team is to be created which include at least infectious disease physician, clinical pharmacist with infectious diseases training and clinical microbiologist to optimize the selection of appropriate antimicrobial agents, dose and duration and that will lead to best outcomes and reduce emergency of resistance due to irrational use of antimicrobial agents.

Soft copies of patient's medication records must be kept to make it easier to assess each treatment individually and to easy the access by treating staff with out violation of privacy and confidentiality of the patients.
References:


1099.


